Sign in
4

Changes in Ownership

Denali Therapeutics Inc. Filed Acc 0001209191-17-065250

Director acquired 25,000 shares (conversion)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Tessier-Lavigne Marc Director 2017-12-12 Conversion +25,000 3,139,043 D
Derivatives
Tessier-Lavigne Marc Director 2017-12-12 Conversion · Series A-1 Preferred Stock −25,000 0 D
Loading xslF345X03/doc4.xml…